Search

CN

搜索
imgboxbg

Products

>
>
>
>
HemaSeq Human 254 Gene Mutation Detection Kit (NGS-for Illumina)
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获2

HemaSeq Human 254 Gene Mutation Detection Kit (NGS-for Illumina)

Product introduction Targeted-capture NGS technology is applied to detect multiple myeloma-related 254 genes simultaneously. SNV, Indel and splicing can be obtained in the core target regions of 254 genes all at once.
Cat. No.:
S0963-S
Spec:
6 rxns/Kit (60 Tests)
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part F_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part A_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part B_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part C_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part D_3504x2613
HemaSeq人类254基因突变检测试剂盒(可逆末端终止测序法)-Part E_3504x2613
捕获2
Product description
Parameters

 

Detection Content

 

 

NGS technology enables the detection of 254 gene mutations of MM at once, including core genes related to disease occurrence, clonal evolution, prognosis evaluation, therapeutic medication, etc., and the genes can be used for MRD monitoring. (see the gene list for details)

 

 

Advantages

 

 

1、Based on authoritative databases (COSMIC, NCCN, MY CANCER GENOME, PHARMGKB, etc.), professional guidelines (WHO, NCCN, guidelines for the diagnosis and management of multiple myeloma in China, etc.) and the latest literature, it covers both common MM gene mutations used for clinical detection, and disease-related genes for clinical research as reported in the literature.


2、Capture probes designed for the target region: all point mutations, small fragment insertions/deletions in the CDS region of 243 genes, and 11 SNP sites associated with chemotherapeutic agents in the gene.


(1) Covers the hotspot genes related to MM clonal evolution, risk stratification, and targeted therapy.


(2) The probe coverage reaches 99.9%, with a capture region of 1 M, suitable for deep sequencing and meeting clinical needs of 2000× detection.


High sensitivity, with accurate and stable detection of more than 1% mutations.

 

Specimen Requirements

 

 

Sample type: Bone marrow: 3–5 ML, tube (purple cap).

 

Target Population

 

 

 

Disease screening: include newly diagnosed MM patients at various stages (including MGUS, sMM, MM, PCL, etc.).


Newly diagnosed MM patients: determine genetic risk, assist patient prognosis, and select appropriate treatment regimens.


Relapsed MM patients: indicate clonal evolution, and determine the type and characteristics of disease progression; conduct MRD monitoring.


MM patients with drug resistance: detect resistance-associated mutations and select appropriate treatment and medication regimens.

 

 

Gene List (only partial genes displayed)

 

 

 

ABCF1

ARID1B

BCL2

BRCA2

CCNE1

CDKN2B

ABI3BP

ARID2

BCL2L11

BRWD3

CD38

CDKN2C

ACTG1

ASXL1

BCL7A

BTG1

CD74

CEP72

ADAMTS9

ATF6

BHLHE41

C8orf34

CDK12

CHEK2

AKT1

ATG3

BIRC2

CARD11

CDK2

CIC

AKT2

ATM

BIRC3

CBFB

CDK4

CKS1B

AKT3

ATR

BLM

CCNA1

CDK6

CNOT3

ALK

ATRX

BMPR1A

CCND1

CDK7

CRBN

ANK2

B2M

BRAF

CCND2

CDKN1B

CREBBP

ARID1A

BAX

BRCA1

CCND3

CDKN2A

CTLA4

 

 

Ordering Information

 

 

Cat. No. Product Strength

 S0963-S

 

HemaSeq Human 254 Gene Mutation Detection Kit
(NGS-for Illumina)

 

6 rxns/Kit

(60 Tests)

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table

Copyright:Wuhan Healthy Biotechnology Co., Ltd.